Advertisement

Zeitschrift für Rheumatologie

, Volume 76, Issue 4, pp 372–374 | Cite as

Adalimumab-induced pulmonary sarcoidosis not progressing upon treatment with etanercept

  • J. H. Jung
  • J.-H. Kim
  • G. G. Song
Kasuistiken

Abstract

Tumor necrosis factor alpha (TNF-α) inhibitors effectively treat sarcoidosis, but can, paradoxically, induce sarcoidosis. The TNF-α inhibitor etanercept is most commonly associated with paradoxical sarcoidosis, which has previously been reported to be resolved by adalimumab. However, we describe the case of a patient with ankylosing spondylitis and adalimumab-induced sarcoidosis not aggravated by switching to etanercept, thus indicating that etanercept could be a treatment option for patients who develop paradoxical sarcoid-like reactions after treatment with other TNF-α inhibitors.

Keywords

Adalimumab Etanercept Pulmonary sarcoidosis Tumor necrosis factor-α Paradoxical response 

Kein Fortschreiten einer Adalimumab-induzierten Lungensarkoidose unter Etanercept

Zusammenfassung

Tumor-Nekrose-Faktor-α(TNF-α)-Inhibitoren sind ein wirksames Therapeutikum der Sarkoidose, können aber paradoxerweise eine Sarkoidose auch induzieren. Der TNF-α-Inhibitor Etanercept ist am häufigsten mit einer paradoxen Sarkoidose assoziiert. Wie berichtet wurde, konnte diese mit Adalimumab kuriert werden. In dieser Kasuistik beschreiben wir jedoch den Fall eines Patienten mit ankylosierender Spondylitis und Adalimumab-induzierter Sarkoidose, die sich nach einem Wechsel zu Etanercept nicht verschlechterte. Daher könnte Etanercept eine Behandlungsoption für Patienten sein, bei denen es nach Therapie mit anderen TNF-α-Inhibitoren zu paradoxen sarkoidähnlichen Reaktionen kommt.

Schlüsselwörter

Adalimumab Etanercept Lungensarkoidose Tumor-Nekrose-Faktor-α Paradoxe Antwort 

Notes

Compliance with ethical guidelines

Conflict of interest

J. H. Jung, J.-H. Kim, and G. G. Song declare that they have no competing interests.

All studies on humans described in the present manuscript were carried out with the approval of the responsible ethics committee and in accordance with national law and the Helsinki Declaration of 1975 (in its current, revised form). Informed consent was obtained from all patients included in studies.

References

  1. 1.
    Burns AM, Green PJ, Pasternak S (2012) Etanercept-induced cutaneous and pulmonary sarcoid-like granulomas resolving with adalimumab. J Cutan Pathol 39:289–293CrossRefPubMedGoogle Scholar
  2. 2.
    Sim JK, Lee SY, Shim JJ, Kang KH (2016) Pulmonary sarcoidosis induced by Adalimumab: a case report and literature review. Yonsei Med J 57:272–273CrossRefPubMedGoogle Scholar
  3. 3.
    Nakajima R, Abe K, Nakajima A, Nishikawa T, Sakai S (2015) Etanercept-induced sarcoidosis in rheumatoid arthritis: FDG PET findings. Clin Nucl Med 40:58–61CrossRefPubMedGoogle Scholar
  4. 4.
    Unterstell N, Bressan AL, Serpa LA, Fonseca E, Castro PP, Gripp AC (2013) Systemic sarcoidosis induced by etanercept: first Brazilian case report. An Bras Dermatol 88:197–199CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Zheng L, Teschler H, Guzman J, Hubner K, Striz I, Costabel U (1995) Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am J Respir Crit Care Med 152:1061–1066CrossRefPubMedGoogle Scholar
  6. 6.
    Saketkoo LA, Baughman RP (2016) Biologic therapies in the treatment of sarcoidosis. Expert Rev Clin Immunol 3:1–9Google Scholar
  7. 7.
    Bhargava S, Perlman DM, Allen TL, Ritter JH, Bhargava M (2013) Adalimumab induced pulmonary sarcoid reaction. Respir Med Case Rep 10:53–55PubMedPubMedCentralGoogle Scholar
  8. 8.
    Utz JP, Limper AH, Kalra S et al (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124:177–185CrossRefPubMedGoogle Scholar
  9. 9.
    Amber KT, Bloom R, Mrowietz U, Hertl M (2015) TNF-α: a treatment target or cause of sarcoidosis? J Eur Acad Dermatol Venereol 29:2104–2011CrossRefPubMedGoogle Scholar
  10. 10.
    Wijnen PA, Cremers JP, Nelemans PJ et al (2014) Association of the TNF-α G‑308A polymorphism with TNF-inhibitor response in sarcoidosis. Eur Respir J 43:1730–1739CrossRefPubMedGoogle Scholar
  11. 11.
    Petrek M (2015) Personalized medicine in sarcoidosis: predict responders and nonresponders. Curr Opin Pulm Med 21:532–537CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  1. 1.Korea University College of MedicineSeoulKorea
  2. 2.Division of Rheumatology, Department of Internal MedicineKorea University Guro HospitalSeoulKorea

Personalised recommendations